Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]

What does the iManageCancer project hope to achieve?

Prof Gordon McVie - ecancer Managing Editor

What does the iManageCancer project hope to achieve? ( Prof Gordon McVie - ecancer Managing Editor )

Mouse models for complex aspects in human cancer

Dr Peter Bouwman - Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

Mouse models for complex aspects in human cancer ( Dr Peter Bouwman - Netherlands Cancer Institute (NKI), Amsterdam, Netherlands )

Prediction of side-effects of anti-cancer drugs

Dr Gerard Milano - Centre Antoine Lacassagne, Nice, France

Prediction of side-effects of anti-cancer drugs ( Dr Gerard Milano - Centre Antoine Lacassagne, Nice, France )

Buparlisib helps overcome endocrine resistance in metastatic breast cancer:...

Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes...

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )

TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer...

Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium

TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )

Molecular evolution of breast cancer during neoadjuvant chemotherapy

Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway

Molecular evolution of breast cancer during neoadjuvant chemotherapy ( Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway )

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally...

Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer ( Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA )

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use...

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )

Trastuzumab emtansine improves overall survival versus treatment of physician's...

Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium

Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response...

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

More from ecancer